Literature DB >> 2598571

Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.

D E Nix1, W A Watson, M E Lener, R W Frost, G Krol, H Goldstein, J Lettieri, J J Schentag.   

Abstract

The effect of an antacid (Maalox) and ranitidine administration on the absorption of ciprofloxacin was evaluated in healthy male volunteers who were enrolled in three separate studies. Each study was designed at a three- or four-period crossover and included the administration of 750 mg ciprofloxacin alone as a control treatment. Treatments that were evaluated included the administration of ciprofloxacin 5 to 10 minutes, 2 hours, 4 hours, and 6 hours after a single 30 ml dose of antacid; the administration of antacid 2 hours after ciprofloxacin was given; and the administration of ciprofloxacin 2 hours after a 200 mg ranitidine tablet. Administration of antacid within 4 hours before ciprofloxacin dose resulted in a significant decrease in ciprofloxacin absorption (p less than 0.05). Percentages of relative bioavailability compared with control values were 15.1%, 23.2%, and 70% for the 5 to 10 minute, 2 hour, and 4 hour antacid pretreatments, respectively. Administration of antacid 6 hours before or 2 hours after the ciprofloxacin dose did not affect absorption. Ranitidine did not alter ciprofloxacin absorption. Antacids that contain magnesium and aluminum salts may reduce the absorption of ciprofloxacin. The extent of this interaction appears to increase as the time between administration of the two drugs decreases. Ranitidine is suggested as an alternative to antacids for patients receiving treatment with ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598571     DOI: 10.1038/clpt.1989.207

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  48 in total

1.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.

Authors:  H Stass; M F Böttcher; K Ochmann
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Effect of antacid medication on the pharmacokinetics of temafloxacin.

Authors:  G R Granneman; U Stephan; B Birner; F Sörgel; D Mukherjee
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

4.  Milk and yoghurt do not impair the absorption of ofloxacin.

Authors:  P J Neuvonen; K T Kivistö
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

5.  Inhibition of norfloxacin absorption by dairy products.

Authors:  K T Kivistö; P Ojala-Karlsson; P J Neuvonen
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 6.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Effects of two cations on gastrointestinal absorption of ofloxacin.

Authors:  M Martínez Cabarga; A Sánchez Navarro; C I Colino Gandarillas; A Domínguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 8.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Effect of oral antacids on disposition of intravenous enoxacin.

Authors:  D E Nix; M E Lebsack; M Chapelsky; A J Sedman; J Busch; A Norman
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Norfloxacin interaction with antacids and minerals.

Authors:  N R Campbell; M Kara; B B Hasinoff; W M Haddara; D W McKay
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.